Researchers have discovered a clue to the mechanism for neuronal degeneration and possible target for a therapeutic approach to these disorders.
People who get less rapid eye movement (REM) sleep may have a greater risk of developing dementia, according to a new study published in the August 23, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. REM sleep is the sleep stage when dreaming occurs.
A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer’s. The experimental technology, developed by Cedars-Sinai and NeuroVision, scans the retina using techniques that can identify beta-amyloid protein deposits that mirror those in the brain.
Cedars-Sinai neuroscience investigators have found that Alzheimer’s disease affects the retina – the back of the eye – similarly to the way it affects the brain. The study also revealed that an investigational, noninvasive eye scan could detect the key signs of Alzheimer’s disease years before patients experience symptoms.
A team led by scientists at St. Jude Children’s Research Hospital and Mayo Clinic has identified a basic biological mechanism that kills neurons in amyotrophic lateral sclerosis (ALS) and in a related genetic disorder, frontotemporal dementia (FTD), found in some ALS patients. ALS is popularly known as Lou Gehrig’s disease. The researchers were led by J. Paul Taylor, M.D., Ph.D., chair of the St. Jude Cell and Molecular Biology Department and a Howard Hughes Medical Institute investigator; and Rosa Rademakers, Ph.D., of the Mayo Clinic in Jacksonville, Florida. The findings appear today in the journal Neuron.
Rutgers and Duke University professors explore how to improve care and reduce the use of antipsychotic medications in nursing homes
In a study looking at brain scans of people with mild loss of thought and memory ability, Johns Hopkins researchers report evidence of lower levels of the serotonin transporter — a natural brain chemical that regulates mood, sleep and appetite.
As Alzheimer’s disease and other forms of dementia continue to become more prevalent, it may not be long before there is a push for legalizing physician-assisted death (PAD) in dementia cases in the United States.American officials must thoroughly consider the moral and social consequences of such an action, says an expert on medical ethics at Washington University in St.
The brains of aged chimpanzees, our closest living relatives, show pathology similar to the human Alzheimer’s disease (AD) brain, according to a new, multi-institution research study.
Researchers from Yale University School of Medicine have discovered that defects in the transport of lysosomes within neurons promote the buildup of protein aggregates in the brains of mice with Alzheimer’s disease. The study, which will be published August 7 in The Journal of Cell Biology, suggests that developing ways to restore lysosome transport could represent a new therapeutic approach to treating the neurodegenerative disorder.
Researchers at Penn Medicine have discovered that a patient’s awareness of a diagnosis of cognitive impairment may diminish their self-assessment of quality of life.
Rita Cowell, Ph.D., has joined the Southern Research as Chair of the Neuroscience Department as it expands research and drug discovery efforts focusing on diseases such as Parkinson’s and Alzheimer’s.
Loyola Medicine is participating in a landmark $100 million study of the effectiveness of using PET scans to detect Alzheimer's disease.
Older adults who consume alcohol moderately on a regular basis are more likely to live to the age of 85 without dementia or other cognitive impairments than non-drinkers, according to a University of California San Diego School of Medicine-led study.
Press can register here to livestream this special session through Newswise Live on Monday, July 31 at 7:30 PM EDT
Diagnosing Alzheimer’s disease and determining a patient’s prognosis is an inexact business, and that stands in the way of better personalized care and advances in treatment. A new study from The Ohio State University has identified a potential new way of confirming the disease and predicting a patient’s outlook.
The push to develop treatments for Alzheimer’s disease has yielded a greater understanding of the disease, but has failed to generate successful new drugs. To blame are the many undefined subtypes of mild cognitive impairment, a precursor to Alzheimer’s disease. But if scientists grouped people with similar types of cognitive impairment, they could more precisely test the impact of investigational drugs, according to findings in a July 28 article in the journal Scientific Reports, a publication of Nature Research.
A new method may help determine whether a person has Alzheimer’s disease or frontotemporal dementia, two different types of dementia that often have similar symptoms, according to a preliminary study published in the July 26, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
In a new study published today, Arizona State University-Banner Health neuroscientist Salvatore Oddo and his colleagues from Phoenix’s Translational Genomics Research Institute (TGen) — as well as the University of California, Irvine, and Mount Sinai in New York — have identified a new way for brain cells to become fated to die during Alzheimer’s diseases.
People who carry a genetic susceptibility to Alzheimer’s disease appear to be at greater risk of diminished cognition from sleep-disordered breathing than those without the susceptibility, according to new research published online, ahead of print in the Annals of the American Thoracic Society.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right